Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer ...

Genetic engineering technologies allow for the creation of custom-made cells that can have transformative effects on human health. This is best exemplified by chimeric antigen receptor (CAR ...

To date, the Food and Drug Administration (FDA) has approved seven chimeric antigen receptor-T (CAR-T) cell therapies and seven bispecific T-cell engagers (BiTEs) across a variety of hematologic ...

A rapidly developed, dual-target chimeric antigen receptor T-cell therapy produced a 100% overall response rate in patients ...

In recent years, CAR-T cell immunotherapy (using chimeric antigen receptors) has revolutionized the fight against cancer. In combination with other tools (chemotherapy, radiotherapy), this new ...

Adoptive T cell therapy using Chimeric Antigen Receptor T cells (CAR T) has made significant advances in the treatment of hematologic malignancies and solid tumors. However, a key challenge remains ...

Our trial provides proof of concept that cytokine-armored CAR T-cell treatment is feasible and may enhance antitumor activity without additional toxic effects,” researchers reported.

Using a multipronged strategy, Celyad is driving the development of next-generation chimeric antigen receptor-T cell-based therapies to treat cancer. Lead programs include both autologous and ...

Beyond the Point: Learning From Outcomes After Inpatient Immune Checkpoint Inhibitor Therapy Chimeric antigen receptor T-cell (CAR-T) therapies are standard of care for the treatment of several ...

A recently developed cancer treatment called chimeric antigen receptor T-cell therapy (CAR T-cell therapy, for short) offers hope to people whose diffuse large B-cell lymphoma (DLBCL) has proved ...

A new chimeric antigen receptor (CAR) T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of ...